European drugs regulator flags rare eye risk with Ozempic
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition.Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday.advertisementThe EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine.
NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma.Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link.Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness.A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes.advertisementThe EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketingsurveillance.It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare".The US Food and Drug Administration did not immediately respond to a Reuters request for comment.Must Watch
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
Fitness coach shares ‘10 low calorie fruits with almost zero calories she ate to lose 25 kg in 4 months'
Eating fruits provides the body with nutrients that can boost overall health. However, some choices, like pineapple and watermelon, can be a delicious addition to a weight loss diet, as per fitness coach Amaka. She said that incorporating a variety of fruits into your weight loss diet, you can add natural sweetness, fibre, and nutrients to support your overall health and weight loss goals. Also read | 7 weight loss myths busted by celebrity fitness trainer Tridev Pandey: 'Never go for Ozempic…' She took to Instagram on June 7 and said, 'Here are 10 fruits that are super low in calories, packed with water and fibre, and perfect for losing weight faster and keeping you full without adding much to your calorie count, I enjoyed to lose 25 kg in 4 months…' Amaka tilted her post: '10 low calorie fruits with almost 0 calories I ate to lose 25 kg in 4 months'. She added veggies like carrots to her list and wrote in her caption, 'You can enjoy these fruits without worrying about calories! And they also help you lose weight faster.' A post shared by CERTIFIED NUTRITIONIST (@shred_with_amaka) Amaka said, 'Rich in over 90 percent water, helps flush out bloating.' She added, 'Super hydrating, due to its high water content, it helps you stay really full and it doubles as a vegetable so you can add it to your meal to give you that bulk (volume) without consuming extra calories, as it's very low in calories and it really. Reduces bloating.' Amaka said, 'Very low in calories, also aids in curbing sugar cravings.' 'Super low in calories, crunchy, and filling,' she added. Amaka further said, 'Super high in fibre, keeps you full.' She added, 'Rich in vitamin C and fibre. Boosts your metabolism and aids digestion.' Amaka said, 'Detoxifies your body and aids digestion. I always add to warm water in the morning and take it as my morning drink.' She added, 'Very rich in water, very sweet and filling, and it curbs appetite naturally.' Amaka said, 'Tasty, crunchy and very satisfying.' She concluded, 'My favourite: contains bromelain that burns belly fat very fast; perfect to take after meals to reduce bloating. Works like magic.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Time of India
3 hours ago
- Time of India
Weight-loss drug bulks up sales as patients upgrade dosage
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.
Economic Times
3 hours ago
- Economic Times
Weight-loss drug bulks up sales as patients upgrade dosage
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.
